For BLCA, primary therapy outcome (partial response (PR)/complete response (CR), HR = 0.42, p-value = 0.003) and ANLN expression (high ANLN, HR = 1.87, p-value = 0.022) were independent prognostic factors (Supplementary Table S2B). The gene discussed is ANLN; the disease is bladder transitional cell carcinoma.